Browsing by Author "Kalyoncu, Umut"

Now showing 1 - 16 of 16

A nationwide experience with the off label use of interleukin 1 targeting treatment in familial mediterranean fever patients
(Wiley, 2016-10-01) Akar, Servet; Çetin, Pınar; Kalyoncu, Umut; Karadağ, Ömer; Sarı, İsmail; Çınar, Muhammed; Yılmaz, Sedat; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Balkarlı, Ayşe; Küçükşahin, Orhan; Öner, Sibel Yılmaz; Şenel, Soner; Tufan, Abdurrahman; Direskeneli, Haner; Öksüz, Mustafa Ferhat; Pehlivan, Yavuz; Bayndır, Özün; Keser, Gökhan; Aksu, Kenan; Omma, Ahmet; Kaşifoğlu, Timuçin; Ünal, Ali Uğur; Yıldız, Fatih; Balcı, Mehmet Ali; Yavuz, Şule; Erten, Şükran; Özgen, Metin; Sayarıoğlu, Mehmet; Doğru, Atalay; Çetin, Gözde Yıldırım; Alibaz-Öner, Fatma; Tezcan, Mehmet Engin; Pamuk, Ömer Nuri; Önen, Fatos; Öksüz, Mustafa Ferhat; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; JXF-7598-2024; AAG-8227-2021
Are there any clues to predict bamboo spine in axial spondyloarthritis?
(Wiley, 2020-10-01) Atagündüz, Pamir; Kiraz, Sedat; Akar, Servet; Küçükşahin, Orhan; Erden, Abdulsamet; Beş, Cemal; Kılıç, Levent; Karadağ, Ömer; Kaşifoğlu, Timuçin; Emmüngil, Hakan; Çınar, Muhammet; Kimyon, Gezmis; Yazısız, Veli; Ateş, Aşkın; Ersözlü, Emine Duygu; Gonullu, Emel; Mercan, Rıdvan; Ertenli, İhsan; Kalyoncu, Umut; Yağız, Burcu; YAĞIZ, BURCU; Coşkun, Nihan; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CLH-7318-2022
Behçet disease with vascular involvement: Effects of different therapeutic regimens on the incidence of new relapses
(Lippincott Williams & Wilkins, 2015-02) Öner, Fatma Alibaz; Karadeniz, Aslı; Yılmaz, Sema; Balkarlı, Ayşe; Kimyon, Gezmiş; Yazıcı, Ayten; Çınar, Muhammet; Yılmaz, Sedat; Yıldız, Fatih; Bilge, Şule Yaşar; Bilgin, Emre; Omma, Ahmet; Çetin, Gözde Yıldırım; Çağatay, Yonca; Karaaslan, Yaşar; Sayarlıoğlu, Mehmet; Kalyoncu, Umut; Karadağ, Ömer; Kaşifoğlu, Timuçin; Erken, Eren; Pay, Salih; Çefle, Ayşe; Kısacık, Bünyamin; Onat, Ahmet Mesut; Çobankara, Veli; Direskeneli, Haner; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-7155-2021; AAG-8227-2021; 55646165400; 13205593600
Vascular involvement is one of the major causes of mortality and morbidity in Behcet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 +/- 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. Asecond vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments. We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.
Current smoking is increased in axial psoriatic arthritis and radiographic sacroiliitis
(Journal of Rheumatology Publishing Co., 2020-09-01) Solmaz, Dilek; Kalyoncu, Umut; Tinazzi, Ilaria; Bakirci, Sibel; Bayindir, Ozun; Dogru, Atalay; Omma, Ahmet; Can, Meryem; Yilmaz, Sema; Erden, Abdulsamet; Aydın, Sibel Zehra; Dalkılıç, Ediz; Uludağ Üniversitesi/İç Hastalıkları Bölümü/Romatoloji Anabilim Dalı; CMF-4757-2022; 6506739457
OBJECTIVE: This study aims to examine how internalized stigma differs in opioid use disorder (OUD) based on sociodemographic and clinical variables, and to what extent internalized stigma is related to treatment motivation, perceived social support, depression, and anxiety levels. METHODS: One hundred forty-five individuals with OUD included. Sociodemographic and clinical data form, the Internalized Stigma of Mental Illness Scale (ISMI), Treatment Motivation Questionnaire (TMQ), Multidimensional Scale of Perceived Social Support, the Beck Depression Inventory, and the Beck Anxiety Inventory were utilized in the study to collect data. Bivariate and partial correlation coefficients between variables were computed. ISMI and TMQ scores were compared between patients with depressive symptoms and patients without depressive symptoms by using t-test and Mann Whitney U test. RESULTS: Internalized stigma was high among male patients with heroin use disorder. There was a positive correlation between internalized stigma score and treatment motivation, depression, and anxiety levels. On the other hand, there was a negative correlation between internalized stigma score and multidimensional perceived social support. CONCLUSION: Internalized stigma occupies an important place in the treatment of OUD, which occurs with frequent relapses and which is hard to treat. Not only application for treatment but also adherence to treatment and treatment motivation at maintenance phase bestow a complicated relationship with depression and anxiety. In the struggle against internalized stigma, it plays a vital role to mobilize people’s social support systems, to educate families on the issue and to get in touch with support units exclusive to heroin users.
Derivation and validation of a new still activity score (SAS)
(Bmj Publishing Group, 2019-06-01) Kalyoncu, Umut; Kaşifoğlu, Timuçin; Omma, Ahmet; Bes, Cemal; Çınar, Muhammet; Emmungil, Hakan; Küçükşahin, Orhan; Akar, Servet; Aksu, Kenan; Yıldız, Fatih; Kanıtez, Nilüfer Alpay; Erden, Abdulsamet; Bilgin, Emre; Turan, Sezin; Dalkılıç, Ediz; Ermurat, Selime; Hayran, Kadir Mutlu; DALKILIÇ, HÜSEYİN EDİZ; Ermurat, Selime; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; JHC-5173-2023; ABE-4424-2022
Disease activity indices and body mass index: Cross-sectional analysis of a large psoriatic arthritis cohort
(Wiley, 2015-10-01) Kalyoncu, Umut; Bayndar, Ozun; Yilmazer, Barış; Dalkılıç, Hüseyin Ediz; Aksu, Kenan; Öksüz, Mustafa Ferhat; Tarhan, E. Figen; Can, Meryem; Küçükşahin, Orhan; Kimyon, Gezmiş; Akyol, Lütfi; Onat, Ahmet Mesut; Kısacık, Bünyamin; Erden, Abdülsamet; Omma, Ahmet; Bakırlı, Duygu Ersözlü; Özişler, Cem; Gönüllü, Emel; Pehlevan, Seval; Solmaz, Dilek; Çınar, Muhammet; Çetin, Gözde; Tufan, Abdurrahman; Tufan, Müge Aydın; Kılıç, Levent; Erten, Şükran; Kaşifoğlu, Timuçin; Kobak, Şenol; Şenel, Soner; Akar, Servet; Özgen, Metin; Kasapoğlu-Günal, Esen; Yazısız, Veli; Yılmaz, Sedat; Dönmez, Salim; Doğan, İsmail; Köseoğlu, Hamide Kart; Erbasan, Funda; Yıldız, Fatih; Beş, Cemal; Balkarlı, Ayşe; Şahin, Ali; Mercan, Rıdvan; Arslan, Fatoş; Doğru, Atalay; Pay, Salih; Yavuz, Şule; Çakır, Necati; Kabasakal, Yasemin; Aydın, Sibel Z.; DALKILIÇ, HÜSEYİN EDİZ; CMF-4757-2022
Factors that may be associated with uveitis in patients with spondyloarthritis
(Wiley, 2018-09-01) Kaşifoğlu, Timuçin; Bilge, Nazife Şule Yaşar; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıc, Ediz; Bes, Cemal; Kanitez, Nilüfer Alpay; Atagündüz, Pamir; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çinar, Muhammed; Ateş, Aşkın; Akar, Servet; Gercik, Onay; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Kimyon, Gezmiş; Tufan, Müge Aydın; Emmungil, Hakan; Mercan, Rıdvan; Bodakçı, Erdal; Öz, Burak; Akar, Zeynel Abidin; Karadağ, Ömer; Keleşoğlu, Bahar; Yılmaz, Sedat; İlgen, Ufuk; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bölümü; CMF-4757-2022
GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey
(Future Medicine, 2021-04-21) Akar, Servet; Kalyoncu, Umut; Dalkılıç, Ediz; Emmüngil, Hakan; Aziz, Ayten; Esen, Yasemin; Koç, Tuba; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022
Aim: To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Materials & methods: Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Patients were classified as biologic-naive and biologic-experienced. Results: The study included 60 RA and 269 ax-SpA patients. At month 24, the retention rates were 67.2 and 57.1% (biologic-naive and biologic-experienced RA) and 74.8 and 80.4% (anti-TNF-naive and -experienced ax-SpA). No significant differences in retention were observed between the biologic-naive and -experienced groups for either disease. Conclusion: The results of this study confirm the effectiveness of GLM in the treatment of RA and axSpA with good retention rates at 2 years in a real-world setting in Turkey.
Impacts of Anti-TNF treatment on improvement in work place and household productivity in patients with psoriatic arthritis
(Wiley, 2016-10) Karadağ, Ömer; Onat, Ahmet Mesut; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Kısacık, Bünyamin; Pamuk, Ömer Nuri; Yılmaz, Neslihan; Koca, Süleyman Serdar; Yazısız, Veli; Ocakcı, Pınar Talu; Sayarlıoğlu, Mehmet; Terzioğlu, Ender; Erten, Sükran; Kalyoncu, Umut; Dalkılıç, Ediz; Öksüz, Mustafa Ferhat; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; CMF-4757-2022; INW-5232-2023
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
(Springer Heidelberg, 2021-07-05) Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Kiraz, Sedat; Yazısız, Veli; Kucuksahin, Orhan; Erden, Abdulsamet; Kanitez, Nilufer Alpay; Kimyon, Gezmis; Emmungil, Hakan; Bilge, Sule Yasar; Kasifoglu, Timucin; Bes, Cemal; Bolek, Ertugrul Cagri; Bilgin, Emre; Karatas, Ahmet; Kelesoglu, Bahar; Ersozlu, Duygu; Gonullu, Emel Orge; Mercan, Ridvan; Yilmaz, Sedat; Karadag, Omer; Akar, Servet; Ertenli, Ihsan; Kalyoncu, Umut; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; 0000-0003-0298-4157 ; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022
We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established in 2017, the TReasure database is a web-based, prospective, observational cohort for Turkey. As of May 2019, there were 2,690 RA patients recorded as receiving biologic and targeted synthetic DMARDs (bDMARDs and tsDMARDs) therapy. At the start of the bDMARDs or tsDMARDs, patients with follow-up visits of at least 3 months were registered. At the time of registration and the last visit, doses of GCs were recorded and it was determined if the target dose of <= 7.5 mg was achieved. During registration and follow-up, 23.4% of the patients did not receive GCs and 76.5% of the patients received GCs at any time. GCs could be stopped after 59 (25-116) months in 28.4% of these patients, but 71.6% of patients were still using GC. The target GC dose could not be achieved in 18.2% of these patients (n = 352). The rate of continuing to use GC was significantly higher in women, in the elderly, those with rheumatoid factor (RF) positive, with higher Visual Analog Scale (VAS) pain and Disease Activity Score (DAS)-28. The initial GC dose of >= 7.5 mg/day was found to be crucial in not reaching the GC target dose (p < 0.001, OR 39.0 (24.1-63.2)). The initial GC dose of >= 7.5 mg/day, female gender, age, RF positivity, high DAS28, and VAS pain level were all highly related for GC continuation. Despite the use of DMARDs, our data revealed that we are still far from achieving our goal of treating RA without using steroids.
Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis
(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.
Psart-id inception cohort: Clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis
(Oxford University, 2021-04-01) Ayan, Gizem; Aydin, Sibel Zehra; Kimyon, Gezmis; Ozisler, Cem; Tinazzi, Ilaria; Dogru, Atalay; Omma, Ahmet; Kilic, Levent; Kucuksahin, Orhan; Gonullu, Emel; Can, Meryem; Ylldlz, Fatih; Solmaz, Dilek; Bayindir, Ozun; Esmen, Serpil Ergulu; Ersozlu, Emine Duygu; Duruoz, Mehmet Tuncay; Akyol, Lutfi; Kucuk, Adem; Bes, Cemal; Erden, Abdulsamet; Bakirci, Sibel; Kasifoglu, Timucin; Kalyoncu, Umut; Balkarli, Aye; Dalkilic, Ediz; Cetin, Gozde Yildirim; Cinar, Muhammet; Mercan, Ridvan; Yazisiz, Veli; Dalkılıç, Ediz; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-1889-9619; 0000-0001-7475-3927; 0000-0002-6990-4206; 0000-0003-3628-8870; 0000-0002-9035-689X; 0000-0003-3584-2788; 0000-0001-8028-1671; 0000-0002-8084-2018; 0000-0002-2745-7700; 0000-0001-9680-7535; 0000-0002-6150-3539; GQQ-3193-2022; I-2307-2016; W-2397-2019; K-7985-2019; B-1448-2016; AAK-7851-2021; HLP-4890-2023; GZA-3287-2022; P-2555-2018; C-1808-2016
Objectives. Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts.Methods. PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n=388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5-10 years (n = 328), >= 10 years (n = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts.Results. The mean (S.D.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA >= 10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months.Conclusion. The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time.
Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study
(Springer London, 2021-08-23) Karadağ, Ömer; Dalkılıç, Ediz; Ayan, Gizem; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Yılmaz, Neslihan; Koca, Süleyman Serdar; Yazısız, Veli; Erten, Pınar Talu; Sayarlıoğlu, Mehmet; Terzioğlu, Mustafa Ender; Erten, Şükran; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022
Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.Method One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.Results A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 +/- 11.1 years and 6.9 +/- 6.5 years, respectively. The most commonly used TNF alpha inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.Conclusions The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.
The impact of ankylosing spondylitis in Turkey on productivity at work outside home and within the household
(Wiley, 2015-10-01) Solmaz, Dilek; Cetin, Pınar; Pamuk, Ömer Nuri; Cefle, Ayşe; Keser, Gökhan; Öztürk, Mehmet Akif; Sayarlıoğlu, Mehmet; Turgay, Murat; İnanc, Nevsun; Sarı, Refik Ali; Akar, Servet; Şener, Soner; Koca, Süleyman Serdar; Kobak, Şenol; Şentürk, Taşkın; Kalyoncu, Umut; Çobankara, Veli; Karaaslan, Yaşar; Pehlivan, Yavuz; Akkoç, Nurullah; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021
What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?
(Clinical & Exper Rheumatology, 2019-09) Bakırcı, Sibel; Solmaz, Dilek; Al Osaimi, Noura; Can, Meryem; Erden, Abdulsamed; Özişler, C.; Çınar, Muhammet; Kılıç, Levent; Küçük, A.; Omma, Ahmet; Yıldız, Fatih; Doğru, Atalay; Esmen, Serpil Ergülü; Akar, Servet; Kalyoncu, Umut; Aydın, Sibel Zehra; Tufan, Abdurrahman; Dalkılıç, Ediz; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022; 6506739457
Objective: Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO). The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA(+) or MDA(-)).MethodsPsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. PsA patients who had at least 1 year of disease duration and had full data for MDA were included for this analysis (n=317). Patients were considered in MDA+ when they met at least 5/7 of the MDA criteria.ResultsMDA was achieved in 46% patients. Within MDA- patients, body surface area (51.2%) and swollen joint count (53.5%) domains could still be achieved in the majority and 93.5% of them had no enthesitis using the Leeds enthesitis index. Of 170 patients with MDA-, 90 patients did not fulfill all 3 PROs of MDA. Mono-arthritis subtype (RR: 2.01), absence of enthesitis (RR: 1.570) and absence of distal interphalangeal (DIP) joint disease (RR: 1.1) were associated with higher probability of achieving MDA.ConclusionThe MDA criteria provide an objective target for treatment in trials and clinical practice; however, in real life PROs are the most significant barriers to achieve MDA. The presence of DIP joints disease makes it difficult to reach MDA due to active PROs.